Type 2 Diabetes
Clinical evidence summaries for type 2 diabetes, including glycaemic therapies, cardiovascular outcomes, kidney protection, complications, technology, obesity, and long-term safety.
Amycretin (Oral GLP-1/Amylin Co-Agonist): First-in-Human Phase 1 Safety Trial
First-in-human phase 1 trial finds the oral GLP-1/amylin co-agonist amycretin safe and well tolerated with dose-dependent gastrointestinal effects; weight and glucose changes were exploratory only. PICO summary and expert commentary.
Once-Weekly IcoSema Matches Daily Basal-Bolus on HbA1c, With Less Weight and Hypoglycaemia (COMBINE 3)
In adults with type 2 diabetes on basal insulin, once-weekly IcoSema was non-inferior to basal-bolus therapy for HbA1c and superior for weight, insulin dose, and hypoglycaemia. PICO summary and expert commentary.
Is IcoSema More Effective Than Insulin Icodec for Type 2 Diabetes?
The phase 3a COMBINE 1 trial finds once-weekly IcoSema lowers HbA1c more than insulin icodec alone while cutting hypoglycemia. PICO summary and expert commentary.
Is the Dulaglutide Biosimilar LY05008 Equivalent to Trulicity in Chinese Adults With Type 2 Diabetes?
A phase 3 open-label trial in 440 Chinese adults found the dulaglutide biosimilar LY05008 equivalent to reference dulaglutide (Trulicity) for HbA1c reduction at 24 weeks. PICO summary and expert commentary.
Does SGLT2 Inhibitor Use Modify Oral Semaglutide’s Cardiovascular Benefit in Type 2 Diabetes?
A prespecified SOUL trial analysis tested whether baseline SGLT2 inhibitor use modified oral semaglutide's cardiovascular benefit in type 2 diabetes. PICO summary and expert commentary.
Once-Weekly Insulin Icodec in Type 2 Diabetes: Consistent Across GLP-1RA and SGLT2i Background Therapy
A post hoc analysis of ONWARDS 1-5 testing whether the efficacy and hypoglycaemia profile of once-weekly insulin icodec versus once-daily basal insulin differs by baseline GLP-1RA or SGLT2i use. PICO summary and expert commentary.
Does iGlarLixi Improve Early Blood Sugar Control in Asians with Type 2 Diabetes?
A post hoc analysis of two randomised trials found iGlarLixi produced larger 12-week HbA1c falls and faster time to target than insulin glargine in Asian adults with type 2 diabetes, though without reported between-group significance testing. PICO summary and expert commentary.